Non-melanoma skin cancers (NMSCs) are the most commonly diagnosed malignancies worldwide. This heterogeneous group includes basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). While BCC and cSCC are typically curable through surgical excision, some patients may develop advanced and metastatic disease with very poor prognoses. Emerging therapies target molecular pathways and immune dysfunction to treat these advanced and metastatic cases more effectively.
Our CATALYST initiative aims to support the multidisciplinary dermatology and oncology care team by providing scientifically rigorous and visually compelling education on managing NMSCs. We empower clinicians to make informed clinical decisions, conduct appropriate risk assessments, educate patients, foster effective communication, and select treatment regimens based on the latest clinical guidelines and trial data. This interactive program aims to help achieve optimal long-term patient outcomes by overcoming barriers to effective management.
Med Learning Group is a full-service, accredited medical education company dedicated to enhancing healthcare practitioners’ ability to deliver optimal patient care through high-quality continuing education. Our primary goal is to improve both practitioner skills and patient outcomes.
Specializing in live and online activities, we offer innovative, case-based, interactive, and patient-centric programs tailored to physicians, nurses, pharmacists, and other healthcare practitioners’ unique needs. As part of our CATALYST mission, we aim to review the latest clinical evidence for immunotherapeutic treatment of advanced cutaneous squamous cell carcinoma and basal cell carcinoma; and apply multidisciplinary strategies for patient care, including risk assessment, communication, and education.
